DRI Healthcare Trust (TSE:DHT.UN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of DRI Healthcare Trust (TSE:DHT.UN) have earned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is C$17.94.

Several equities research analysts recently issued reports on the stock. Raymond James reduced their target price on shares of DRI Healthcare Trust from C$23.00 to C$22.00 in a report on Wednesday, November 13th. Scotiabank increased their price objective on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Finally, CIBC lowered their target price on shares of DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a research note on Thursday, December 12th.

DRI Healthcare Trust Price Performance

TSE:DHT.UN opened at C$12.00 on Monday. The stock has a 50-day simple moving average of C$12.85 and a two-hundred day simple moving average of C$12.99. DRI Healthcare Trust has a 52-week low of C$10.39 and a 52-week high of C$17.43.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.